Chemical Shift Encoding-based Water-fat Magnetic Resonance Imaging in Spinal Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Qizheng Wang
- Phone Number: 13161593501
- Email: wangqizheng96@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100089
- Recruiting
- Peking University Third Hospital
-
Contact:
- Ning Lang
- Phone Number: +861082265571
- Email: langning800129@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pathological biopsy of a patient with diagnosed spinal tumor lesion, and preoperative examination Chemical shift encoding-based water-fat MRI was performed.
Exclusion Criteria:
- Recurrent neoplasms; Lesion diameter < 1 cm; Poor image quality.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with benign spinal tumor
|
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
|
|
Patients with intermediate spinal tumor
|
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
|
|
Patients with malignant spinal tumor
|
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Type of tumor
Time Frame: One month before treatment
|
Pathological diagnosis
|
One month before treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Ning Lang, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M2022403
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Tumor
-
NCT04968730Recruiting
-
NCT05664438RecruitingSpinal Cord Tumor of Cervical Spine
-
NCT05856370RecruitingSpinal Deformity | Spinal Degenerative Disorder | Spinal Trauma | Spinal Fusion Failure | Spinal Tumor Case
-
NCT03052738CompletedBrain Tumor | Spinal Tumor | Central Nervous System Tumor
-
NCT06120426RecruitingSurgery | Radiotherapy | Spinal Tumor | Malignant Bone Tumor | Spinal Metastases
-
NCT06613295RecruitingSolid Tumor | Spinal Tumor | Spinal Neoplasms
-
NCT06023212Recruiting
-
NCT06140927RecruitingSpinal Stenosis | Spine Fusion | Spine Tumor
Clinical Trials on Chemical shift encoding-based water-fat MRI
-
NCT07609225Not yet recruitingMetastatic Castration-resistant Prostate Cancer
-
NCT02539836CompletedObesity | Body Weight | Intestinal Bacteria Flora Disturbance
-
NCT07535229Enrolling by invitation
-
NCT06657209RecruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Pre Diabetes
-
NCT02068794Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma
-
NCT04370301RecruitingPrimary Myelofibrosis | Secondary Myelofibrosis